VF
SABS icon

Virtu Financial’s SAB Biotherapeutics SABS Stock Holding History

Virtu Financial’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-37,943
Closed -$145K – 2163
2026
Q1 		$145K Buy
+37,943
New +$151K 0.01% 1113
2025
Q4 		– Sell
-19,982
Closed -$40K – 2154
2025
Q3 		$40K Buy
+19,982
New +$45.2K ﹤0.01% 1166
2023
Q3 		– Sell
-2,490
Closed -$21K – 1818
2023
Q2 		$21K Buy
2,490
+989
+66% +$8.1K ﹤0.01% 1254
2023
Q1 		$7K Buy
+1,501
New +$9.49K ﹤0.01% 1377
2022
Q1 		– Sell
-1,538
Closed -$120K – 1964
2021
Q4 		$120K Buy
+1,538
New +$144K 0.01% 1054

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Virtu Financial's SABS Position: Q2 2026 in Review

Virtu Financial sold out of SAB Biotherapeutics (SABS) in Q2 2026, closing a stake of 37,943 shares — an estimated $145K sold.

Virtu Financial first reported a position in SABS in Q4 2021 and held it in 5 quarters. The position peaked at $145K in Q1 2026. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Virtu Financial reported no remaining SAB Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Virtu Financial sold 37,943 SAB Biotherapeutics shares in Q2 2026, an estimated $145K.
  • Virtu Financial first reported a position in SAB Biotherapeutics in Q4 2021 and held it in 5 quarters.
  • Virtu Financial's SAB Biotherapeutics position peaked at $145K in Q1 2026.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.